10-Q: Verano Q2 Revenue Drops Amid Market Pressures

Verano Holdings Corp. reported a 9% decline in Q2 2025 revenue to $202.3 million, driven by accounts receivable strategy and price compression, despite new store openings and acquisitions.

Summary

• Revenue, net of discounts, for Q2 2025 decreased by 9.0% to $202,272 thousand, compared to $222,390 thousand in Q2 2024.
• Revenue, net of discounts, for H1 2025 decreased by 7.1% to $412,081 thousand, compared to $443,696 thousand in H1 2024.
• The decrease in revenue was primarily driven by the company's accounts receivable strategy (maintaining accounts on hold for non-payment) and expected third-party price compression in established markets.
• Gross profit for Q2 2025 was $112,984 thousand (55.9% margin), a slight decrease from $114,340 thousand (51.4% margin) in Q2 2024.
• Gross profit for H1 2025 was $212,565 thousand (51.6% margin), a decrease from $227,300 thousand (51.2% margin) in H1 2024.
• Net loss attributable to Verano Holdings Corp. & Subsidiaries for Q2 2025 was $(19,150) thousand, an improvement from $(21,764) thousand in Q2 2024.
• Net loss attributable to Verano Holdings Corp. & Subsidiaries for H1 2025 was $(30,665) thousand, an increase from $(26,586) thousand in H1 2024.
• Cash and cash equivalents as of June 30, 2025, were $68,569 thousand, down from $87,796 thousand as of December 31, 2024.
• Net cash provided by operating activities for H1 2025 was $12,686 thousand, a decrease from $38,962 thousand in H1 2024.
• Total current liabilities as of June 30, 2025, were $147,832 thousand, down from $197,968 thousand as of December 31, 2024.
• Working capital increased to $223,524 thousand as of June 30, 2025, from $159,541 thousand as of December 31, 2024.
• The company opened three new stores in Q2 2025 (Connecticut, Florida, Ohio) and five in H1 2025 (two in Connecticut, two in Florida, one in Ohio).
• Darren Weiss resigned as President on August 1, 2025, and subsequently entered into a consulting agreement with the company for services outside North America.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company improved its Q2 net loss and gross margin, the significant revenue decline, decrease in cash, and reduced operating cash flow are concerning. The ongoing large legal dispute and the general federal illegality of cannabis add substantial risk. The company's explanation for revenue decline (accounts on hold, price compression) indicates market challenges.

Positives

• Net loss decreased by $2,614 thousand in Q2 2025 compared to Q2 2024, improving to $(19,150) thousand.
• Gross profit margin improved to 55.9% in Q2 2025 from 51.4% in Q2 2024, and to 51.6% in H1 2025 from 51.2% in H1 2024, driven by more efficient harvests from expanded cultivation facilities.
• Selling, General, and Administrative (SG&A) expenses decreased by $729 thousand (0.8%) in Q2 2025 and $6,439 thousand (3.6%) in H1 2025, reflecting ongoing efficiencies across the business.
• A Gain on Debt Extinguishment of $2,947 thousand was recognized in Q2 2025 due to a voluntary partial payoff agreement for the CC East Virginia Promissory Note.
• A Gain on Deconsolidation of $4,739 thousand was recognized in H1 2025 related to the termination of contracts for Arkansas operations.
• Working capital increased by $63,983 thousand to $223,524 thousand as of June 30, 2025, primarily due to an increase in inventory and held-for-sale assets.
• The company was in compliance with all financial covenants under its 2022 Credit Agreement as of June 30, 2025.
• Expansion of retail footprint with three new store openings in Q2 2025 and five in H1 2025, including new stores from acquisitions (CC East Virginia and Cannabist AZ) and increased sales in the Florida market.

Negatives

• Revenue decreased by 9.0% in Q2 2025 and 7.1% in H1 2025, primarily due to the company's accounts receivable strategy of maintaining accounts on hold for non-payment and expected third-party price compression in established markets.
• Net loss increased by $4,079 thousand in H1 2025 compared to H1 2024, reaching $(30,665) thousand.
• Cultivation (wholesale) revenue decreased significantly by 20.7% in Q2 2025 and 14.4% in H1 2025, attributed to the accounts receivable strategy, increased competition in New Jersey and Illinois, and strategic allocation of materials for new product development.
• Cash and cash equivalents decreased by $19,227 thousand from $87,796 thousand on December 31, 2024, to $68,569 thousand on June 30, 2025.
• Net cash provided by operating activities decreased by $26,276 thousand in H1 2025 compared to H1 2024, largely driven by an increase in inventory.
• Provision for income taxes increased by $4,622 thousand (15.1%) in Q2 2025 and $10,494 thousand (25.0%) in H1 2025.
• SG&A expenses as a percentage of revenue increased to 42.7% in Q2 2025 from 39.2% in Q2 2024, and to 41.5% in H1 2025 from 40.0% in H1 2024.
• The company is involved in ongoing litigation with Vireo Growth Inc. (GGH), which is seeking $860,900 thousand in damages, plus costs and interest.

Risks

• The illegality of cannabis under U.S. federal law, which could result in significant fines, penalties, administrative sanctions, convictions, civil forfeiture, or divestiture, despite state-level legalization.
• Uncertainty regarding the passage of comprehensive U.S. federal legislation to de-schedule and de-criminalize cannabis, and no guarantee that such legislation, if passed, would preserve current state-based cannabis programs or be favorable to the company.
• Impacts of economic uncertainty stemming from disruptions in U.S. and global markets, inflation, rising interest rates, and changes in consumer and business confidence.
• Risks related to outstanding indebtedness and potential future indebtedness, including the ability to repay such indebtedness.
• Reliance on key management personnel.
• Market acceptance of existing and new products, and potential returns or recalls of products.
• The accuracy of forecasted demand for products.
• Potential for fraudulent activity by employees, contractors, and consultants.
• Exposure to growth-related operational and execution risks.
• Potential negative findings in clinical research with respect to products.
• Ongoing litigation matter with Vireo Growth Inc., formerly known as Goodness Growth Holdings, Inc., which could have a material adverse effect.
• Potential product liability claims.
• Exposure to natural phenomena and resulting potential uninsured or underinsured losses.
• The risk that property will be subject to civil asset forfeiture due to federal cannabis laws.
• Reliance on the performance of subsidiaries and affiliates due to the company's structure.
• Risks associated with the expansion-by-acquisition strategy, including the ability to acquire businesses and cannabis licenses in desired markets, the integration and operation of acquired businesses, and the typically limited operations of businesses acquired.
• The unconventional due diligence process in the cannabis industry.
• The ability to acquire and lease properties suitable for the cultivation, production, and sale of cannabis.
• Potential limited representations and warranties of businesses that may be acquired.
• Acquisition of businesses in developing cannabis markets.
• Lack of portfolio diversification by industry or geography.
• Risks associated with the use of joint ventures, strategic partnerships, and alliances.
• Contractual relationships with consolidated variable interest entities.
• Existing competition and new market entrants in the cannabis industry.
• The introduction of synthetic alternatives to cannabis products by pharmaceutical and other companies.
• The immaturity of the cannabis industry and limited comparable, competitive, and established industry best practices.
• The availability of and reliance on third-party suppliers, service providers, contractors, and manufacturers, and any significant interruption of these relationships.
• Changes in U.S. trade policy, including the imposition of tariffs and resulting consequences.
• Wholesale and retail price fluctuations.
• Public opinion and perception of the cannabis industry.
• The availability of raw or other materials.
• Rising or volatile energy costs.
• Agricultural and environmental risks and the impacts of environmental regulations on the cannabis industry.
• Physical security risks, such as theft.
• Potential scrutiny from Canadian authorities.
• Disparate state-by-state regulatory landscapes and licensing regimes for medical and adult-use cannabis.
• Difficulties cannabis businesses face accessing and maintaining banking or financial services due to federal regulations.
• The cost and difficulty of complying with various regulatory schemes.
• The impact of state social equity legislation as it relates to the cannabis industry.
• The risk of high bonding and insurance costs.
• Effects of changes in laws and policies governing employees and by union organizing activity.
• Potential divestment of licenses if required by regulatory authorities.
• Dependency on the banking industry.
• Required public disclosure and governmental filings containing personal information of officers, investors, and other stakeholders.
• Potential findings by regulatory authorities that one of shareholders is unsuitable.
• The risk that directors, officers, employees, or investors are barred from entering the U.S.
• The ability to, and constraints on, promoting and marketing cannabis products.
• Potential U.S. Food and Drug Administration governance of the cannabis industry.
• Potential limitations on the ability to enforce contracts or any liens granted.
• The potential lack of access to federal bankruptcy protections in the U.S.
• Reliance on information technology systems, the potential disclosure of personal information of patients and customers, and cybersecurity risks.
• Reliance on third-party software providers.
• Costs related to preserving brand identity.
• The ability to protect intellectual property due to limited intellectual property protections available for cannabis products and potential infringement by third parties.
• Potential infringement or misappropriation claims.
• The risk of financial crimes.
• The risk of receiving no return on securities.
• Elimination of monetary liability and indemnification rights against directors, officers, and employees under British Columbia law.
• The dual class capital structure with Class A subordinate voting shares and Class B proportionate voting shares.
• The time and resources necessary to comply with corporate governance practices and securities rules and regulations in the U.S. and Canada.
• Management's ability to maintain effective internal controls.
• Potential dilution if additional Subordinate Voting Shares or Proportionate Voting Shares are issued.
• Market perception of sales of a substantial amount of Subordinate Voting Shares.
• Transfer restrictions on Subordinate Voting Shares.
• Price volatility of Subordinate Voting Shares.
• Shareholders' limited participation in affairs.
• The expectation not to declare or pay out dividends.
• The concentration of voting control.
• The taxation of cannabis companies in the U.S., including the impact of Section 280E of the Internal Revenue Code of 1986, as amended, which limits deductible expenses.

Future Outlook

The company's strategy prioritizes expansion and revenue growth by exploring new markets, opening or acquiring new dispensary locations, and scaling production. It anticipates pressure on margins in cultivation (wholesale) and retail channels as state markets mature, expecting operational optimization to partially offset price compression at the wholesale level. Selling costs are projected to increase slightly with facility and market expansion. Management believes internally generated funds and other liquidity sources will be sufficient for working capital, capital expenditures, and business needs for at least the next 12 months. Long-term liquidity requirements are expected to be met through future debt or equity issuances, net cash from operations, and other borrowings. The company expects to retain additional cash from operations due to its position on Section 280E of the Code and is currently evaluating the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its 2025 effective tax rate and cash tax position.

Management Comments

• Our strategy is to vertically integrate as a single cohesive company in multiple states through the consolidation of seed-to-sale cultivating, manufacturing, distributing, and dispensing cannabis brands and products at scale.
• Our cultivation, processing and wholesale distribution of cannabis consumer packaged goods are designed to guarantee shelf-space in our national retail dispensary chains, as well as to develop and foster long term wholesale supply relationships with third-party retail operators.
• Our model includes geographic diversity by establishing a footprint to allow us to adapt to changes in both industry and market conditions.
• The Company's expansion and revenue growth strategy has taken priority and will continue to do so for the foreseeable future as it expands its footprint, by exploring new markets and opening or acquiring new dispensary locations, and scales production within certain markets.
• In the core markets in which the Company is already operational and, as the state markets mature, the Company anticipates that there will be pressure on margins in the cultivation (wholesale) and retail channels.
• The Company's current production capacity has not been fully realized and it is expected that price compression at the cultivation (wholesale) level, will be partially offset by operational optimization.
• The Company takes a cautious approach in allocating its capital to maximize its returns while ensuring appropriate liquidity.
• Given inflation and the uncertainty of the future economic environment, the Company has taken additional measures in monitoring and deploying its capital to minimize the potentially negative impact on its operations and expansion plans.
• We believe that internally generated funds and other sources of liquidity discussed below will be sufficient to meet working capital needs, capital expenditures, and other business requirements for at least the next 12 months.
• We believe we will meet known or reasonably likely future cash requirements through the combination of cash generated from operating activities, available cash balances and available borrowings.
• We expect to meet our long-term liquidity requirements through various sources of capital, which may include future debt or equity issuances, net cash provided by operations and other secured and unsecured borrowings.
• We believe that the foregoing sources of capital will provide sufficient funds for our operations, anticipated expansion and scheduled debt payments for the long-term.
• Our ability to fund our operating needs will depend on our future ability to continue to generate positive cash flow from operations and our ability to obtain debt or equity financing on acceptable terms.
• The Company expects to retain additional cash from operations, due in part to the Company's treatment of Section 280E of the Code as not applying to limit its deduction of ordinary and necessary business expenses.

Industry Context

The U.S. cannabis industry continues to operate on a state-by-state basis due to federal illegality, with 39 states plus DC and territories having comprehensive medical cannabis programs, and 24 states plus DC and territories authorizing both medical and adult-use cannabis. The company operates in 13 states, navigating disparate regulatory landscapes. The filing notes increased competition and promotional activity, particularly in New Jersey and Illinois, which is consistent with broader trends observed among multi-state cannabis operators. The launch of Ohio's adult-use program in August 2024 represents a significant market development. The recent enactment of the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, which makes certain tax provisions permanent, could impact the tax landscape for cannabis companies, including the company's effective tax rate and cash tax position.

Comparison to Industry Standards

• The company noted increased competition and promotional activity in New Jersey and Illinois, stating this is 'consistent with other multi-state cannabis operators,' indicating its performance in these markets aligns with broader industry trends.

Management Changes

Legal Proceedings

• Ongoing litigation with Vireo Growth Inc. (GGH) in the Supreme Court of British Columbia, initiated by GGH on October 21, 2022, alleging breach of the Arrangement Agreement, duty of good faith, and duty of honest performance.
• The company filed a counterclaim on November 14, 2022, asserting GGH owes a termination fee of $14,875 thousand or reimbursement of up to $3,000 thousand in out-of-pocket expenses.
• On May 2, 2024, GGH filed an application for summary trial seeking $860,900 thousand in damages, plus costs and interest.
• On June 19, 2024, the company filed an application seeking dismissal of GGH's summary trial application and inadmissibility of GGH's damages report.
• On September 17, 2024, the company filed an amended response and counterclaim.
• The company cannot guarantee prevailing or settling this lawsuit on favorable terms, and an adverse outcome could have a material adverse effect on its business, results of operations, and financial condition.

Related Party Transactions

• George Archos, the Chairman and Chief Executive Officer, participated as a Lender in the 2022 Credit Agreement, funding $1,000 thousand.
• The company sold products to Two Pointo, LLC and two associated entities on a wholesale basis, totaling $854 thousand (net of discounts) in Q1 2024 and $1,321 thousand (net of discounts) in Q2 2024, with $552 thousand due as of December 31, 2024.
• Darren Weiss (former President) and David Spreckman (Chief Marketing Officer) previously received profit interests in Two Pointo, LLC, which were voluntarily forfeited in 2024.
• Maria Fragias, an immediate family member of George Archos, was the beneficiary of a trust that held ownership and profit interests in Two Pointo, LLC, which were divested in 2024.
• The company leases real property for a retail dispensary in Aurora, Illinois, from 740 Rte. 59, LLC, in which George Archos holds an indirect 50% ownership interest. Payments were $46 thousand for Q2 2025 and Q2 2024, and $92 thousand for H1 2025 and H1 2024.
• The company leases real property for a retail dispensary in Lombard, Illinois, from 783 Butterfield LLC, in which George Archos holds a 50% indirect ownership interest. Payments were $93 thousand for Q2 2025 and $91 thousand for Q2 2024, and $185 thousand for H1 2025 and $182 thousand for H1 2024.
• The company paid Sweed High Tech Holdings, Inc. (a point of sale software provider) $1,696 thousand for services during H1 2025 and $1,382 thousand during the year ended December 31, 2024. GP Management Group, LLC, an entity beneficially owned and controlled by George Archos, held an ownership interest of less than 1% in Sweed as of June 30, 2025.

Stakeholder Impact

• Shareholders face potential dilution if the company issues equity for future capital raises, along with risks of price volatility and limited participation in company affairs. No dividends are expected.
• Employees may be affected by changes in laws and policies governing employment and potential union organizing activity. The resignation of the President is a notable management change.
• Customers may benefit from increased competition and promotional activity in certain markets (e.g., New Jersey and Illinois), potentially leading to better pricing or deals. The company's loyalty programs offer discounts.
• Creditors are impacted by the company's debt obligations, though the company reported compliance with all debt covenants as of June 30, 2025.
• Suppliers and contractors face risks related to the company's reliance on third-party relationships, potential supply chain disruptions, and increased pricing due to changes in trade policy.

Next Steps

• Continue to implement the strategy to vertically integrate and expand the company's footprint by exploring new markets and opening or acquiring new dispensary locations.
• Scale production within certain markets to optimize operations and partially offset anticipated price compression at the cultivation (wholesale) level.
• Maintain a cautious approach in allocating capital to maximize returns and ensure appropriate liquidity, especially given inflation and economic uncertainty.
• Evaluate the provisions of the One Big Beautiful Bill Act (OBBBA) and its potential effects on the estimated annual effective tax rate and cash tax position for the year ending December 31, 2025.

Key Dates

Recommendation

While Verano Holdings Corp. demonstrated some operational improvements, such as an improved gross margin and reduced SG&A expenses, the significant decline in revenue and reduced operating cash flow are concerning. The ongoing, substantial litigation with Vireo Growth Inc. and the inherent risks of operating in the federally illegal U.S. cannabis market introduce considerable uncertainty. The company's liquidity position, while deemed sufficient for short-term needs, indicates a reliance on potential future capital raises for long-term growth. A seasoned investor would likely hold to monitor if the company can reverse the revenue trend, effectively manage its legal exposure, and successfully navigate the complex and evolving regulatory landscape.

Keywords

Cannabis, Multi-state operator, MSO, Cultivation, Retail, Dispensary, Medical cannabis, Adult-use cannabis, SEC filing, 10-Q, Financial results, Earnings, Revenue, Gross profit, Net loss, Debt, Acquisitions, Risk factors, Section 280E, US federal cannabis law, Verano Holdings Corp.